Bottom Line
K-bio is not one theme but a landscape where three businesses of different risk structure — CDMO (capacity), platform out-licensing (royalties), biosimilars (patent cliff) — sit under a single name.
2025 out-licensing topped KRW 20 trillion for the first time. The index fell double digits in the first half, but capacity, platform, and the patent cliff stand as three distinct cash-flow structures.
K-bio is not one theme but a landscape where three businesses of different risk structure — CDMO (capacity), platform out-licensing (royalties), biosimilars (patent cliff) — sit under a single name.
2025 out-licensing topped KRW 20 trillion for the first time, yet healthcare was left out of the H1 2026 KOSPI bull market. Alteogen's 2% royalty disclosure (Merck US filing, Jan 2026) etched the lesson that value is set by royalties, not headline deal value.
Structural beneficiaries — Samsung Biologics with the world's largest capacity (CDMO); Alteogen and Yuhan with proven platforms and actual royalty receipts (out-licensing); Celltrion with proven earnings quality (biosimilars). Pressure variables — clinical failure, low royalty-rate disclosure, US drug-price regulation, a strong won and Chinese CDMO price competition.
Hanmi efpeglenatide domestic Phase 3 result and launch (H2 2026), Samsung Biologics Plant 6 progress (2027), Alteogen new licensing and royalty-rate disclosure, LigaChem J&J option exercise, Lilly orforglipron and Novo oral Wegovy distribution.
In 2025, Korean pharma-bio out-licensing (transferring rights to a drug candidate under development to an overseas pharma in exchange for fees and royalties) topped KRW 20 trillion for the first time. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association counted 19 deals for the year, more than double the prior year. The industry's fundamentals plainly leveled up.
Yet the stocks went the other way. In the first half of 2026, with the KOSPI more than doubling in a roaring bull market, healthcare and pharma indices fell by double digits through the half. Money crowded into chips, shipbuilding, and defense; bio was left out. An industry record and stock neglect overlapped in the same six months.
The trigger for the neglect was a single disclosure. Alteogen holds a platform that converts intravenous drugs to subcutaneous injection, and its Keytruda contract with Merck revealed — via Merck's own US accounting filing in January 2026 — a of just 2% of net sales. That was less than half the 4-6% the market had expected. The stock fell more than 22% in one day, erasing roughly KRW 6 trillion in market value in a single session.
The lesson is clear. The value of an out-licensing deal is set not by headline deal value (milestones, staged success payments) but by the royalty actually collected. The market now looks past the big number in the contract to the probability that number is realized.
Split this way, what each axis hinges on becomes sharp. K-bio is not one theme but a landscape where three businesses with entirely different risk structures sit under a single name.
Sign in with Google to unlock the full body of every free report instantly.
Sign in with GoogleThis site runs on ads — the tier system rewards community contributions.
This report is provided for informational purposes only and does not constitute a recommendation to buy or sell any financial instrument. Investment decisions should be made based on your own judgment and responsibility. The analysis and opinions contained herein are based on information available at the time of writing and are subject to change.